In myeloma, excessive ADAR1 activity leads to the R701G mutation through RNA editing of Glioma-associated oncogene 1 (GLI1) transcription, affecting cancer cell proliferation and resistance to anticancer drugs [123]. This evidence concerns the gene ADAR and plasma cell myeloma.